Total neoadjuvant therapy vs standard therapy in locally advanced rectal cancer: a systematic review and meta-analysis A Kasi, S Abbasi, S Handa, R Al-Rajabi, A Saeed, J Baranda, W Sun JAMA network open 3 (12), e2030097-e2030097, 2020 | 234 | 2020 |
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: a real‐world study A D’Alessio, CAM Fulgenzi, N Nishida, M Schönlein, J von Felden, ... Hepatology 76 (4), 1000-1012, 2022 | 148 | 2022 |
Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study ZA Wainberg, PC Enzinger, YK Kang, S Qin, K Yamaguchi, IH Kim, ... The Lancet Oncology 23 (11), 1430-1440, 2022 | 106 | 2022 |
Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: a multicenter international cohort study CA Nebhan, A Cortellini, W Ma, T Ganta, H Song, F Ye, R Irlmeier, ... JAMA oncology 7 (12), 1856-1861, 2021 | 96 | 2021 |
Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline MA Shah, EB Kennedy, AE Alarcon-Rozas, T Alcindor, AN Bartley, ... Journal of Clinical Oncology 41 (7), 1470-1491, 2023 | 80 | 2023 |
T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma M Barsch, H Salié, AE Schlaak, Z Zhang, M Hess, LS Mayer, C Tauber, ... Journal of Hepatology 77 (2), 397-409, 2022 | 79 | 2022 |
Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review GR Mohyuddin, M Aziz, A Britt, L Wade, W Sun, J Baranda, R Al-Rajabi, ... BMC cancer 20, 1-9, 2020 | 63 | 2020 |
High specificity in circulating tumor cell identification is required for accurate evaluation of programmed death-ligand 1 JL Schehr, ZD Schultz, JW Warrick, DJ Guckenberger, HM Pezzi, ... PLoS One 11 (7), e0159397, 2016 | 60 | 2016 |
Immunotherapy in hepatocellular cancer patients with mild to severe liver dysfunction: adjunctive role of the ALBI grade DJ Pinato, T Kaneko, A Saeed, T Pressiani, A Kaseb, Y Wang, D Szafron, ... Cancers 12 (7), 1862, 2020 | 58 | 2020 |
The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma: a review on the rationale and results of … A Saeed, R Park, W Sun Journal of Hematology & Oncology 14, 1-11, 2021 | 57 | 2021 |
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study P Fessas, A Kaseb, Y Wang, A Saeed, D Szafron, T Jun, S Dharmapuri, ... Journal for immunotherapy of cancer 8 (2), 2020 | 56 | 2020 |
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study CAM Fulgenzi, J Cheon, A D'Alessio, N Nishida, C Ang, TU Marron, L Wu, ... European Journal of Cancer 175, 204-213, 2022 | 54 | 2022 |
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: evidence from an FDA pooled analysis of landmark clinical trials with validation … DJ Pinato, TU Marron, PS Mishra-Kalyani, Y Gong, G Wei, D Szafron, ... European Journal of Cancer 157, 140-152, 2021 | 53 | 2021 |
The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma A Muhammed, CAM Fulgenzi, S Dharmapuri, M Pinter, L Balcar, ... Cancers 14 (1), 186, 2021 | 51 | 2021 |
Immune therapeutics in the treatment of advanced gastric and esophageal cancer R Park, S Williamson, A Kasi, A Saeed Anticancer Research 38 (10), 5569-5580, 2018 | 51 | 2018 |
Treatment-related adverse events of combination immune checkpoint inhibitors: systematic review and meta-analysis R Park, L Lopes, CR Cristancho, IM Riano, A Saeed Frontiers in oncology 10, 258, 2020 | 46 | 2020 |
Programmed cell death-ligand 1 (PD-L1) expression in anal cancer R Govindarajan, S Gujja, ER Siegel, A Batra, A Saeed, K Lai, JD James, ... American journal of clinical oncology 41 (7), 638-642, 2018 | 44 | 2018 |
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score … B Marinelli, E Kim, A D'Alessio, M Cedillo, I Sinha, N Debnath, M Kudo, ... Journal for immunotherapy of cancer 10 (6), 2022 | 42 | 2022 |
Early antibiotic exposure is not detrimental to therapeutic effect from immunotherapy in hepatocellular carcinoma P Fessas, M Naeem, M Pinter, TU Marron, D Szafron, L Balcar, A Saeed, ... Liver Cancer 10 (6), 583-592, 2021 | 39 | 2021 |
Anti-PD-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis R Park, L Lopes, A Saeed Clinical and Translational Oncology 23, 100-109, 2021 | 34 | 2021 |